Christiane Angermann Angermann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1192998/publications.pdf Version: 2024-02-01

		471061	433756
31	1,614	17	31
papers	citations	h-index	g-index
32	32	32	1725
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages. Clinical Research in Cardiology, 2023, 112, 868-879.	1.5	4
2	Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the <scp>REPORTâ€HF</scp> registry. European Journal of Heart Failure, 2022, 24, 645-652.	2.9	18
3	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine, 2022, 28, 568-574.	15.2	341
4	Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2224-2234.	1.0	22
5	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation, 2022, 146, 279-288.	1.6	65
6	Sexâ€specific bimodal clustering of left ventricular ejection fraction in patients with acute heart failure. ESC Heart Failure, 2022, 9, 786-790.	1.4	8
7	Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from <scp>REPORTâ€HF</scp> (International Registry to assess <scp>mEdical</scp> Practice with) Tj ETQq1 1 0.7843 Failure, 2022	14 rgBT /(2.9	Overlock 10
8	Failure, 2022 Trajectories of Left Ventricular Ejection Fraction After Acute Decompensation for Systolic Heart Failure: Concomitant Echocardiographic and Systemic Changes, Predictors, and Impact on Clinical Outcomes. Journal of the American Heart Association, 2021, 10, e017822.	1.6	13
9	Heart and brain interactions. Herz, 2021, 46, 138-149.	0.4	24
10	Sodium–glucose coâ€ŧransporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <scp>EMPULSE</scp> trial. European Journal of Heart Failure, 2021, 23, 826-834.	2.9	60
11	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute HeartÂFailure. JACC: Heart Failure, 2021, 9, 349-359.	1.9	14
12	Dynamics of Left Ventricular Myocardial Work in Patients Hospitalized for Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 1393-1403.	0.7	4
13	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. JAMA Cardiology, 2020, 5, 401.	3.0	51
14	Pulmonary artery pressureâ€guided therapy in ambulatory patients with symptomatic heart failure: the <scp>CardioMEMS E</scp> uropean <scp>M</scp> onitoring <scp>S</scp> tudy for <scp>H</scp> eart <scp>F</scp> ailure (<scp>MEMSâ€HF</scp>). European Journal of Heart Failure, 2020, 22, 1891-1901.	2.9	142
15	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. The Lancet Global Health, 2020, 8, e411-e422.	2.9	104
16	Symptom patterns and clinical outcomes in women versus men with systolic heart failure and depression. Clinical Research in Cardiology, 2019, 108, 244-253.	1.5	23
17	The trialist's perspective: what do you need to prove for remote monitoring devices to be approved?. European Heart Journal Supplements, 2019, 21, M57-M60.	0.0	5
18	Point-of-care B-type natriuretic peptide and portable echocardiography for assessment of patients with suspected heart failure in primary care: rationale and design of the three-part Handheld-BNP program and results of the training study. Clinical Research in Cardiology, 2018, 107, 95-107.	1.5	15

CHRISTIANE ANGERMANN

#	Article	IF	CITATIONS
19	Depression, Anxiety, and Cognitive Impairment. Current Heart Failure Reports, 2018, 15, 398-410.	1.3	65
20	Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). Clinical Research in Cardiology, 2018, 107, 991-1002.	1.5	37
21	Prognostic significance of serial high-sensitivity troponin I measurements following acute cardiac decompensation-correlation with longer-term clinical outcomes and reverse remodelling. International Journal of Cardiology, 2017, 232, 199-207.	0.8	11
22	Prevalence and clinical impact of iron deficiency and anaemia among outpatients with chronic heart failure: The PrEP Registry. Clinical Research in Cardiology, 2017, 106, 436-443.	1.5	85
23	Prognostic potential of midregional proâ€adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides. European Journal of Heart Failure, 2017, 19, 1166-1175.	2.9	30
24	A functional variant of the neuropeptide S receptorâ€l gene modulates clinical outcomes and healthcare utilization in patients with systolic heart failure: results from the Interdisciplinary Network Heart Failure (<scp>INH</scp>) Study. European Journal of Heart Failure, 2017, 19, 314-323.	2.9	13
25	High evening salivary cortisol is an independent predictor of increased mortality risk in patients with systolic heart failure. International Journal of Cardiology, 2016, 203, 69-73.	0.8	22
26	Prognostic Value of Aldosterone and Cortisol in Patients Hospitalized for Acutely Decompensated Chronic Heart Failure With and Without Mineralocorticoid Receptor Antagonism. Journal of Cardiac Failure, 2015, 21, 208-216.	0.7	17
27	International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORTâ€HF): rationale for and design of a global registry. European Journal of Heart Failure, 2015, 17, 527-533.	2.9	52
28	Nurseâ€coordinated collaborative disease management improves the quality of guidelineâ€recommended heart failure therapy, patientâ€reported outcomes, and left ventricular remodelling. European Journal of Heart Failure, 2015, 17, 442-452.	2.9	103
29	Comparative Potential of the 2-Item Versus the 9-Item Patient Health Questionnaire to Predict Death or Rehospitalization in Heart Failure. Circulation: Heart Failure, 2015, 8, 464-472.	1.6	41
30	Clinical characteristics, treatment and survival in patients with systolic heart failure — Comparative assessment of a Chinese and a German cohort. International Journal of Cardiology, 2014, 176, 1388-1390.	0.8	4
31	Mode of Action and Effects of Standardized Collaborative Disease Management on Mortality and Morbidity in Patients With Systolic Heart Failure. Circulation: Heart Failure, 2012, 5, 25-35.	1.6	209